Show simple item record

dc.contributor.authorMéroc, Estelle
dc.contributor.authorFröberg, Janeri
dc.contributor.authorAlmasi, Timea
dc.contributor.authorAskeland Winje, Brita
dc.contributor.authorOrrico-Sánchez, Alejandro
dc.contributor.authorSteens, Anneke
dc.contributor.authorMcDonald, Scott A.
dc.contributor.authorBollaerts, Kaatje
dc.contributor.authorKnol, Mirjam J.
dc.identifier.citationBMC Infectious Diseases. 2021, 21 (345), 1-9.en_US
dc.description.abstractBackground: To guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia. Methods: We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019. Results: Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC. Conclusion: This study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.en_US
dc.description.sponsorshipThe VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, and EFPIA-members.en_US
dc.relation.ispartofseriesBMC Infectious Diseases;21, Article number: 345 (2021)
dc.rightsNavngivelse 4.0 Internasjonal*
dc.subjectInfectious diseasesen_US
dc.subjectElderly peopleen_US
dc.subjectDisease burdensen_US
dc.subjectPublic healthen_US
dc.titleEuropean data sources for computing burden of (potential) vaccine-preventable diseases in ageing adultsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.rights.holder© The Author(s). 2021en_US
dc.source.journalBMC Infectious Diseasesen_US
dc.relation.projectInnovative Medicines Initiative 2 Joint Undertaking: 806776en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal